Special Issue "When the Anticancer Strategies Modulating Oxidative Stress Meet Nanomedicine: New Perspectives"

A special issue of Antioxidants (ISSN 2076-3921).

Deadline for manuscript submissions: closed (31 January 2020).

Special Issue Editors

Dr. Stefania Pizzimenti
E-Mail Website
Guest Editor
University of Turin, Department of Clinical and Biological Sciences, Torino, Italy
Interests: lipid peroxidation and cancer; chemoresistance and oxidative stress; nanomedicine to overcome chemoresistance
Dr. Monica Argenziano
E-Mail Website
Guest Editor
University of Turin, Department of Drug Science and Technology, Torino, Italy
Interests: design and development of innovative nanotechnology-based drug delivery systems for cancer and other diseases

Special Issue Information

Dear colleagues,

Although contradictory findings have been reported, the link between oxidative stress and tumours has become more and more evident in the last decades. Cancer cells exhibit elevated reactive oxygen species (ROS) levels, which can contribute, with different mechanisms, to the malignant transformation and progression of tumours. ROS scavenging compounds have been used in chemoprevention and at the early stage of treating tumours. However, very conflicting results have been obtained, so the use of antioxidants in cancer prevention needs to be carefully evaluated. On the other hand, the induction of oxidative stress can be toxic to cancer cells, potentially inducing apoptotic cell death. Thus, strategies with the goal of increasing the ROS level, directly, with prooxidant drugs (e.g. doxorubicin, menadione), or indirectly, by lowering the cellular antioxidant defences, have been used for effective cancer therapies.

Advances in the developing field of nanomedicine can further expand the possibilities of redox-anticancer treatments. Indeed, the use of nanoparticles (NPs) offers many advantages as drug carrier system, by improving the solubility of poorly water-soluble drugs, increasing drug half-life, improving bioavailability and diminishing the drug metabolism. Both antioxidant and pro-oxidant NPs (containing compounds that can reduce or enhance oxidative stress, respectively), as well as redox-sensitive NPs (in most cases containing disulfide bonds to achieve a stimuli-responsive drug release) have been investigated in cancer therapy. Moreover NPs per se can be redox active (e.g. cerium oxide/nanoceria), thus expanding the potential for their therapeutic use.

This Special Issue welcomes original research and reviews of literature concerning tumour chemoprevention and cancer progression studies of redox nanosystems, such as NPs per se redox active or containing conventional chemotherapic medicines, new alternative compounds, molecularly targeted cancer drugs, or nucleic acids with both antioxidant or pro-oxidant properties, as well as redox stimulus-responsive nanocarriers.

Dr. Stefania Pizzimenti
Dr. Monica Argenziano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antioxidants
  • Reactive oxygen species (ROS)
  • Glutathione (GSH)
  • Nuclear factor erythroid 2-related factor 2 (Nrf2)
  • Redox signalling pathways
  • Chemoresistance
  • Transformation
  • Tumour progression
  • Nanomedicine
  • Nanoparticles
  • Redox-sensitive nanoparticles

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Polyurea Dendrimer Folate-Targeted Nanodelivery of l-Buthionine sulfoximine as a Tool to Tackle Ovarian Cancer Chemoresistance
Antioxidants 2020, 9(2), 133; https://doi.org/10.3390/antiox9020133 - 03 Feb 2020
Abstract
: Ovarian cancer is a highly lethal disease, mainly due to chemoresistance. Our previous studies on metabolic remodeling in ovarian cancer have supported that the reliance on glutathione (GSH) bioavailability is a main adaptive metabolic mechanism, also accounting for chemoresistance to conventional therapy [...] Read more.
: Ovarian cancer is a highly lethal disease, mainly due to chemoresistance. Our previous studies on metabolic remodeling in ovarian cancer have supported that the reliance on glutathione (GSH) bioavailability is a main adaptive metabolic mechanism, also accounting for chemoresistance to conventional therapy based on platinum salts. In this study, we tested the effects of the in vitro inhibition of GSH synthesis on the restoration of ovarian cancer cells sensitivity to carboplatin. GSH synthesis was inhibited by exposing cells to l-buthionine sulfoximine (l-BSO), an inhibitor of -glutamylcysteine ligase (GCL). Given the systemic toxicity of l-BSO, we developed a new formulation using polyurea (PURE) dendrimers nanoparticles ([email protected]G4-FA2), targeting l-BSO delivery in a folate functionalized nanoparticle. Full article
Open AccessArticle
Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic and Pro-Oxidant Effect on Human Neuroblastoma Cells
Antioxidants 2020, 9(1), 50; https://doi.org/10.3390/antiox9010050 - 06 Jan 2020
Abstract
Etoposide (ETO) is a cytotoxic drug that exerts its effect by increasing reactive oxygen species (ROS) production. Although ETO is widely used, fast metabolism, poor solubility, systemic toxicity, and multi-drug resistance induction all limit its administration dosage and its therapeutic efficiency. In order [...] Read more.
Etoposide (ETO) is a cytotoxic drug that exerts its effect by increasing reactive oxygen species (ROS) production. Although ETO is widely used, fast metabolism, poor solubility, systemic toxicity, and multi-drug resistance induction all limit its administration dosage and its therapeutic efficiency. In order to address these issues, a biodegradable dendrimer was prepared for entrapping and protecting ETO and for enhancing its solubility and effectiveness. The achieved dendrimer complex with ETO (CPX 5) showed the typical properties of a well-functioning delivery system, i.e., nanospherical morphology (70 nm), optimal Z-potential (−45 mV), good drug loading (37%), very satisfying entrapment efficiency (53%), and a remarkably improved solubility in biocompatible solvents. In regards to its cytotoxic activity, CPX 5 was tested on neuroblastoma (NB) cells with very promising results. In fact, the dendrimer scaffold and ETO are able to exert per se a cytotoxic and pro-oxidant activity on human NB cells. When CPX 5 is combined with ETO, it shows a synergistic action, slowly releasing the drug over time and significantly improving and protracting bioactivity. On the basis of these findings, the prepared ETO reservoir represents a novel biodegradable and promising device for the delivery of ETO into NB cells. Full article
Show Figures

Graphical abstract

Open AccessArticle
Silver Nanoparticles Induce Mitochondrial Protein Oxidation in Lung Cells Impacting Cell Cycle and Proliferation
Antioxidants 2019, 8(11), 552; https://doi.org/10.3390/antiox8110552 - 14 Nov 2019
Abstract
Silver nanoparticles (AgNPs) are widely used nanomaterials in both commercial and clinical biomedical applications, due to their antibacterial properties. AgNPs are also being explored for the treatment of cancer in particular in combination with ionizing radiation. In this work, we studied the effects [...] Read more.
Silver nanoparticles (AgNPs) are widely used nanomaterials in both commercial and clinical biomedical applications, due to their antibacterial properties. AgNPs are also being explored for the treatment of cancer in particular in combination with ionizing radiation. In this work, we studied the effects of AgNPs and ionizing radiation on mitochondrial redox state and function in a panel of lung cell lines (A549, BEAS-2B, Calu-1 and NCI-H358). The exposure to AgNPs caused cell cycle arrest and decreased cell proliferation in A549, BEAS-2B and Calu-1, but not in NCI-H358. The mitochondrial reactive oxygen species (ROS) and protein oxidation increased in a time- and dose-dependent manner in the more sensitive cell lines with the AgNP exposure, but not in NCI-H358. While ionizing radiation also induced changes in the mitochondrial redox profiles, in general, these were not synergistic with the effects of AgNPs with the exception of NCI-H358 and only at a higher dose of radiation. Full article
Show Figures

Graphical abstract

Back to TopTop